



June 23, 2026

Christina Bryan

Vice President of External Affairs

ChristianaCare

Janice E. Nevin, MD, MPH
President & CEO
DHA Board Chair

Bayhealth

Terry Murphy
President & CEO
DHA Board Vice-Chair

TidalHealth Nanticoke

Penny Short, MSM, BSN, RN
President
DHA Board Secretary & Treasurer

Beebe Healthcare

David A. Tam, MD, MBA
President & CEO

Saint Francis Hospital

Le-Ann Harris, DNP, MHA, RN,
NEA-BC
President, Trinity Health Mid-Atlantic

Nemours Children's Health

Laura Kowal, MPT, JD
President
Delaware Valley

Delaware Healthcare Association

Brian W. Frazee
President & CEO

The Honorable Marie Pinkney
411 Legislative Ave
Dover, DE 19901

RE: DHA Supportive Comments on the Regulation of Kratom (HS 1 for HB 332)

Dear Senator Pinkney,

On behalf of the Delaware Healthcare Association, representing Delaware's hospitals, health systems, and related healthcare organizations, thank you for the opportunity to provide comments on House Substitute 1 for House Bill 332.

HS 1 for HB 322 would increase transparency in the marketing and selling of kratom and prohibits the sale of the product to individuals under the age of 21. Delaware has made significant progress in reducing overdose deaths over the past five years. DHA supports the intent of this bill to improve the safety of kratom use and reduce the risk of overdose.

We appreciate that you and Representative Ross Levin worked with DHA in amending the bill to remove the reporting requirement from the bill. Delaware hospitals report overdose data to the Department of Health and Social Services, but they do not have a reliable way to identify whether an overdose is kratom-related unless the patient self-reports kratom use. We look forward to continued collaboration to explore effective ways to collect data on kratom use in our state.

Thank you for the opportunity for DHA to comment on HS 1 for HB 332.

Sincerely,

A handwritten signature in blue ink that reads 'Christina Bryan'.

Christina Bryan
Vice President of External Affairs